amyloid precursor protein

δ-secretase inhibitor 11是一种分泌酶抑制剂，可用作 阿尔茨海默病（AD） 治疗转化开发的先导化合物。

β-Amyloid precursor protein (96-110), cyclized (human) 为一种淀粉样前体蛋白衍生物，特别适用于阿尔茨海默病相关研究。

Beta-Amyloid Protein Precursor 770 (135-155)Aβ Protein Precursor 770 (135-155)

ELN318463 racemate (ELN 318463 racemate) 是 ELN318463 的外消旋体，ELN318463 是一种淀粉样前体蛋白 (APP) 选择性 γ-分泌酶抑制剂。

Atabecestat (JNJ-54861911) 是一种具有口服活性和脑渗透性的 β-位淀粉样蛋白前体蛋白裂解酶 1 (BACE1) 抑制剂，减缓临床前阿尔茨海默病参与者的认知能力下降。Atabecestat 可用于研究阿尔茨海默氏病。

DSS30 是一种 P25 CDK5抑制剂。DSS30通过抑制淀粉样前体蛋白裂解酶1 (BACEl) 磷酸化，减少 β-淀粉样蛋白 (Aβ) 的分泌发挥作用。DSS30 可用于预防和治疗阿尔茨海默病等神经退行性疾病。

BMS 299897 是一种磺胺类 γ 分泌酶抑制剂。它在稳定过表达淀粉样前体蛋白（APP）的 HEK293 细胞中抑制 Aβ 生成的 IC50 值为 7 nM。

Aftin-4 是一种 β-淀粉样蛋白42(Aβ42) 的诱导剂。

Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. It is a potent α4β2 nAChR agonist and inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of the amyloid precursor protein.

BACE1-IN-5 (Compound 15) 是一种 BACE1抑制剂，IC50为 9.1 nM。BACE1-IN-5还可抑制细胞 Aβ，IC50为 0.82 nM。并且，BACE1-IN-5 具有改善 hERG 抑制和 P-gp 外排的药物化学作用。

ELN 318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC50s of 12 nM and 656 nM for PS1 and PS2, respectively. ELN 318463 is 51-fold more selective for PS1.ELN 318463 is an amyloid precursor protein (APP) selective γ-secretase inhibitor.

PF-06751979 is an inhibitor of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) (IC50 of 7.3 nM in BACE1 binding assay).

Umibecestat 是一种β-位点淀粉样前体蛋白裂解酶-1 (BACE-1) 抑制剂，对人 BACE-1 和小鼠 BACE-1 的 IC50 分别为 11 nM 和 10 nM，可用于阿尔茨海默病的研究。

Begacestat (GSI-953)是一种有效和选择性的γ-分泌酶抑制剂 (gamma-secretase) ，以纳摩尔效价抑制Amyloid-β的生成，在细胞水平的Notch切割实验中选择性地抑制对APP切割，逆转情境记忆缺陷，可用于研究阿尔兹海默症。

Aβ aggregation-IN-1 (Compound 1b) 是一种淀粉样蛋白-β (amyloid-beta) 前体蛋白抑制剂，抑制amyloid-beta聚集和纤维形成，其IC50值分别为3.92 M和7.19 M。该化合物还可抑制神经元细胞中的丙二醛生成，并提高细胞内还原谷胱甘肽 (GSH) 水平，同时抑制caspase 3。

Leucyl-phenylalanine amide is an intermediate in the synthesis of γ-Secretase Inhibitor, the enzyme complex that catalyzes the cleavage of the amyloid precursor protein (APP) to produce amyloid β-peptide (Aβ) which is the major causative agent in Alzheime

LY3202626, an amyloid precursor protein secretase (BACE protein) inhibitor, is used for the treatment of Alzheimer's disease.

BACE-IN-1 是淀粉样前体蛋白 β-分泌酶抑制剂。

BACE-IN-1 acetate (BACE-IN-1 acetate (350228-37-4，Free base)) 已被用作 BACE1 抑制剂测定中的 β 位淀粉样前体蛋白 (APP) 裂解酶-1 (BACE1) 抑制剂。 β-位点淀粉样前体蛋白 (APP) 切割酶-1 (BACE1)是一种天冬氨酸蛋白酶，属于蛋白酶家族，由六个腔内半胱氨酸残基组成。这些残基有助于形成三个分子间二硫键和 N-连接的糖基化位点。

Usmarapride free base (SUVN-D4010 free base) 是一种可透过血脑屏障且具有口服活性和选择性的 5-HT4 受体部分激动剂，可提高可溶性淀粉样蛋白前体蛋白 α 的水平，可用于研究阿尔茨海默病。

16F16 is a protein disulfide isomerase (PDI) inhibitor.1It inhibits PDI reductase activity in an enzyme assay when used at concentrations ranging from 1 to 100 μg/ml.116F16 reduces PC12 cell apoptosis induced by the misfolded huntingtin protein HTTQ103. It suppresses PDI-dependent mitochondrial outer membrane permeabilization (MOMP) in isolated PC12 cell mitochondria. 16F16 (2, 3, 4, and 10 μM) reduces HTTN90Q73mutant huntingtin-induced medium spinal neuron death and MOMP in rat corticostriatal slices. It also reduces pyramidal neuron death induced by amyloid-β precursor protein (APP) in rat corticostriatal slices. 1.Hoffstrom, B.G., Kaplan, A., Letso, R., et al.Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteinsNat. Chem. Biol.6(12)900-906(2010)

Donecopride is a partial agonist of the serotonin (5-HT) receptor subtype 5-HT4E(Ki= 8.5 nM) and an inhibitor of acetylcholinesterase (AChE; IC50= 16 nM).1It is selective for AChE over butyrylcholinesterase (BChE; IC50= 3,530 nM) but does bind to 5-HT2Band sigma-2 (σ2) receptors (Ki= 1.6 nM for both) in a panel of 42 neurotransmitter receptors and transporters. Donecopride induces release of soluble amyloid precursor protein-α (sAPP-α) in COS-7 cells transiently expressing 5-HT4with an EC50value of 11.3 nM. Oral administration of donecopride (1 mg/kg) reduces brain soluble and insoluble amyloid-β (1-42) levels and increases the time spent exploring the novel object in the novel object recognition (NOR) test in the 5XFAD transgenic mouse model of Alzheimer's disease. Donecopride (3 mg/kg, p.o.) prevents a reduction in spontaneous alternation behavior induced by intracerebroventricular administration of soluble Aβ42 (sAβ42) in the Y-maze in mice.2 1.Lecoutey, C., Hedou, D., Freret, T., et al.Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatmentProc. Natl. Acad. Sci. USA111(36)E3825-E3830(2014) 2.Rochais, C., Lecoutey, C., Hamidouche, K., et al.Donecopride, a Swiss army knife with potential against Alzheimer's diseaseBr. J. Pharmacol.177(9)1988-2005(2020)

Rasagiline-13C3is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo(ED50= 0.1 mg kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease. 1.Youdim, M.B.H., Gross, A., and Finberg, J.P.Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BBrit. J. Pharmacol.132(2)500-506(2001) 2.Youdim, M.B.H., and Weinstock, M.Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]Cell. Mol. Neurobiol.21(6)555-573(2001) 3.Kang, S.S., Ahn, E.H., Zhang, Z., et al.α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's diseaseEMBO J.37(12)e98878(2018)

TML-6, an oral curcumin derivative, demonstrates inhibitory effects on the synthesis of β-amyloid precursor protein and β-amyloid (Aβ). Additionally, TML-6 exhibits upregulation of Apo E, suppression of NF-κB and mTOR, and enhancement of the anti-oxidative Nrf2 gene activity. Considering its diverse pharmacological profile, TML-6 holds promise as a valuable research tool for investigating Alzheimer's disease (AD)[1].